Context:
Our client sought to evaluate the real-world effectiveness and economic impact of a new once-monthly injectable treatment for schizophrenia. The primary objective was to generate robust evidence to support market access and reimbursement discussions with payers.

Resolution:
We assembled a specialized HEOR team with deep expertise in real-world data analytics. Using large-scale healthcare claims data, the team assessed treatment adherence, hospitalization rates, and associated healthcare costs. They quantified the economic benefits of improved adherence and produced actionable evidence for health technology assessment (HTA) submissions and payer decision-making.

Result:
The analysis revealed a 25% reduction in hospitalization rates among adherent patients and significant estimated annual cost savings. These insights strengthened the client’s reimbursement submissions and facilitated favorable market access decisions across multiple regions.